2020
DOI: 10.1016/s2213-2600(20)30079-5
|View full text |Cite|
|
Sign up to set email alerts
|

Abstract: Background An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia.Methods In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the inte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

571
9,332
133
487

Year Published

2020
2020
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 8,879 publications
(10,523 citation statements)
references
References 20 publications
571
9,332
133
487
Order By: Relevance
“…However, case-control studies and cohort studies are necessary to define the clinical evolution of disease better. A second stage, as occurs in SARS, is maybe also seen in COVID-19, with the lower respiratory tract bilateral compromise, observed in more than 72% of the patients across nine studies with more than 500 patients, also experiencing a dry cough, and dyspnea [5,48,52] and with chest X-ray images of ground-glass opacity frequently observed in two-thirds of patients -this is also seen in SARS [53].…”
Section: Discussionmentioning
confidence: 88%
“…However, case-control studies and cohort studies are necessary to define the clinical evolution of disease better. A second stage, as occurs in SARS, is maybe also seen in COVID-19, with the lower respiratory tract bilateral compromise, observed in more than 72% of the patients across nine studies with more than 500 patients, also experiencing a dry cough, and dyspnea [5,48,52] and with chest X-ray images of ground-glass opacity frequently observed in two-thirds of patients -this is also seen in SARS [53].…”
Section: Discussionmentioning
confidence: 88%
“…In support of this observation, the Chinese authorities have recently issued a directive to regulate and coordinate clinical trials studying potential pharmacological treatments for COVID-19 [11]. The results of these trials will be the first available on humans, since studies published to date on the characteristics and management of patients with COVID-19 did not report data about chloroquine use [1,[12][13][14][15]. Of note, the WHO published a generic protocol for randomized clinical trials to investigate the clinical efficacy and safety of drugs in hospitalized patients with COVID-19 (i.e.…”
Section: Discussionmentioning
confidence: 99%
“…With severe respiratory infection and hypoxia, especially in the setting of severe infection and ARDS due to COVID-19, it is likely that a number of patients will develop such injury. Elevated serum troponin levels have been described in many patients infected with COVID-19, with significant differences noted between patients who died and those who survived to discharge (21,44). In a meta-analysis of 4 studies including a total of 341 patients, standardized mean difference of cardiac troponin I levels were significantly higher in those with severe COVID-19 related illness compared to those with non-severe disease (25.6, 95% CI 6.8-44.5) (45).…”
Section: Myocardial Injury Myocarditis and Acute Coronary Syndromesmentioning
confidence: 99%
“…While the predominant presenting symptoms of COVID-19 are respiratory, a case report described a patient in Italy with chest pain and electrocardiographic changes for which the cardiac catheterization lab was activated. Notably, the patient was found to be free of obstructive coronary artery disease but ultimately tested positive for COVID-19 (50 (44,52).…”
Section: Myocardial Injury Myocarditis and Acute Coronary Syndromesmentioning
confidence: 99%